In addition, as sequential treatment of 5-aza-CdR and HDAC inhibitor is more effective in inducing cell death [44], we were led to consider whether HDACI increases uptake of 5-aza-CdR into DNA or decreases removal of incorporated 5-aza-CdR from DNA, thus enhancing 5-aza-CdR-induced cytotoxicity.
PCT consists of eight individual sessions once a week, offered as sequential treatment after response to A-CT.
We suggest these treatments would be suitable for use in combination as sequential treatments against prostate cancer.
The second study reporting a head-to-head comparison with an aromatase inhibitor was BIG 1 98, comparing letrozole with tamoxifen as monotherapy and as sequential treatments.
The aim of this study was to establish the effects of doxorubicin and vinorelbine, as single agents, in combination, and as sequential treatments, on signal transduction and p53 in the breast cancer cell lines MCF-7 and MDA-MB-468.
In the attempt to address in part this issue, we conducted a series of studies with different RCC models, in vitro and in nude mice, evaluating the activity of sunitinib, sorafenib and everolimus, either as single agents in front line or as sequential treatments, on tumour growth and on the expression and function of a panel of key effectors involved in cell proliferation and angiogenesis.
Thus, only 15 patients completed 14 days with ATRA and 10 days with cytarabine therapy together with continuous valproic acid treatment, and 14 of these patients received this therapy as a sequential treatment during the initial 24 days.
Next, Kennedy et al 26 compared cognitive therapy and lithium augmentation as a sequential treatment option for 44 outpatients with major depression who had a partial response during 8 14 weeks of antidepressant treatment in an 8-week randomised controlled trial.
M-VAC showed encouraging efficacy and reversible toxicities in patients who had progressed after GC chemotherapy and, especially, M-VAC appears to be a reasonable option as a sequential treatment regimen in patients who responded previously to GC chemotherapy.
In addition to guiding treatment decisions, a better understanding of prognostic factors in MBC, particularly in the increasingly smaller subgroup of patients with HER2-positive disease, may lead to improved clinical trial design to evaluate new therapeutic agents and/or concurrent and sequential treatment combinations as well as dual HER2-targeting strategies.
The exploratory data we present here is intended to help modelling such study concepts by identifying prognostic factors in a cohort of LMBC patients both with and without extrahepatic disease who were not amenable to radical surgery and received locally ablative (RFA or BT) or locoregional intrahepatic (RE) treatment either once or in combination as part of sequential treatment decisions.
